

Biosafety Documentation:

iCell[®] DopaNeurons TMEM175 393M/M, 65Q/P

Donor ID	01279	Cell Line ID	01279.1295
Donor Sex	Male	Genotype	TMEM175 393M/M, 65Q/P
Starting Material	Blood	Catalog #	C1273, C1274
Age at Collection	50 - 59 years		
Race	Caucasian		
Ethnicity	Unknown		

Cell Source and Biosafety Level Classification

iCell[®] products are human cells differentiated from a master bank of stably induced pluripotent stem (iPS) cells. FUJIFILM Cellular Dynamics, Inc. (FCDI), classifies these cells as Biosafety Level 1 (BSL1) based on the United States Centers for Disease Control and Prevention publication: *Biosafety in Microbiological and Biomedical Laboratories*. Handle the cells according to the biosafety guidelines applicable in your region.

Reprogramming

The iPS cell line was generated from human peripheral blood through ectopic expression of reprogramming factors by episomal transfection.

Polymerase chain reaction analysis did not detect episomal plasmids in the iPS cell line.

Engineering

The iPS cells were engineered to express neomycin resistance under the control of a neuronal-specific promoter. A puromycin resistance cassette was also included in the targeting vectors to enable selection of the engineered iPS cell line.

The resulting engineered iPSC line was further engineered to change the TMEM175 393M/T heterozygous SNP to a TMEM175 393M/M homozygous status. This line was also engineered to contain a TMEM175 65Q/P heterozygous SNP. No additional drug selection cassettes remain as a result of this correction engineering.

None of the engineering vectors used contain oncogenes.

Infectious Disease Testing

The incoming peripheral blood was tested and non-reactive for HBV, HCV, HIV-1, and HIV-2.

In addition, the cell line was tested and non-reactive for HTLV1, HTLV2, HAV, Hantavirus, HSV1, HSV2, HCMV, HHV6, HHV8, HAAdV, HPV16, HPV18, LCMV, VZV, EBV and syphilis.